ALMS · Alumis Inc. Common Stock
View on chartInsiders & Stakes
| AyurMaya Capital Management Company, LP Director | ▲ Buy | Grant | 15,139,707 Shares held | 5/21/2025 | View profile |
| Foresite Capital Management V, LLC 10% Owner | ▲ Buy | Open Market | 4,202,670 Shares held | 7/1/2024 | View profile |
| Srinivas Akkaraju Director | ▲ Buy | Open Market | 2,298,783 Shares held | 9/8/2026 | View profile |
| Foresite Labs, LLC 10% Owner | ▼ Sell | Other | 680,486 Shares held | 4/1/2026 | View profile |
| Foresite Capital Management VI LLC 10% Owner | ▼ Sell | Other | 680,486 Shares held | 4/1/2026 | View profile |
| James B. Tananbaum Director | ▼ Sell | Other | 680,486 Shares held | 4/1/2026 | View profile |
| Roy C. Hardiman Chief Business & Legal Officer | ▼ Sell | Open Market | 207,746 Shares held | 8/3/2026 | View profile |
| Babler Martin President, CEO and Chairman | ▲ Buy | Open Market | 106,454 Shares held | 4/1/2025 | View profile |
| Jorn Drappa Chief Medical Officer | ▼ Sell | Open Market | 56,892 Shares held | 8/3/2026 | View profile |
| Mark Christopher Bradley Chief Development Officer | ▼ Sell | Open Market | 48,533 Shares held | 8/3/2026 | View profile |
| Richardson Derrick SVP, People and Culture | ▲ Buy | Grant | 42,800 Shares held | 7/29/2025 | View profile |
| Klein Sara General Counsel - Corp Secy | ▲ Buy | Grant | 33,796 Shares held | 7/1/2024 | View profile |
| David M. Goldstein Chief Scientific Officer | ▼ Sell | Open Market | 30,970 Shares held | 8/3/2026 | View profile |
| Zhengbin Yao | ▲ Buy | Grant | 27,082 Shares held | 6/30/2026 | View profile |
| John R. Schroer Chief Financial Officer | ▼ Sell | Open Market | 24,718 Shares held | 8/3/2026 | View profile |
| Colowick Alan Director | ▲ Buy | Open Market | 18,404 Shares held | 4/2/2025 | View profile |
| Sanam Pangali Chief Legal Officer | ▼ Sell | Open Market | 9,747 Shares held | 8/3/2026 | View profile |
| Lynn A. Tetrault Director | ▲ Buy | Grant | 3,553 Shares held | 6/30/2026 | View profile |
| Sapna Srivastava Director | ▲ Buy | Grant | 3,553 Shares held | 6/30/2026 | View profile |
| Patrick Machado Director | ▲ Buy | Grant | 3,553 Shares held | 6/30/2026 | View profile |
Transaction History
| Srinivas Akkaraju | ▼ Sell | Open Market | 48,066 | $507K | 9/8/2026 |
| Srinivas Akkaraju | ▼ Sell | Open Market | 48,065 | $507K | 9/8/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 273,291 | $2.9M | 9/8/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 273,290 | $2.9M | 9/8/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 220,070 | $2.5M | 9/4/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 220,070 | $2.5M | 9/4/2026 |
| John R. Schroer | ▼ Sell | Open Market | 3,282 | $87K | 8/3/2026 |
| Sanam Pangali | ▼ Sell | Open Market | 1,364 | $36K | 8/3/2026 |
| Roy C. Hardiman | ▼ Sell | Open Market | 2,692 | $71K | 8/3/2026 |
| David M. Goldstein | ▼ Sell | Open Market | 2,596 | $68K | 8/3/2026 |
| Jorn Drappa | ▼ Sell | Open Market | 2,447 | $65K | 8/3/2026 |
| Mark Christopher Bradley | ▼ Sell | Open Market | 2,572 | $68K | 8/3/2026 |
| Sanam Pangali | ▲ Buy | Option Exercise | 5,000 | $25K | 7/6/2026 |
| Sanam Pangali | ▼ Sell | Open Market | 5,000 | $140K | 7/6/2026 |
| Lynn A. Tetrault | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 |
| Zhengbin Yao | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 |
| Sapna Srivastava | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 |
| Patrick Machado | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 |
| Srinivas Akkaraju | ▲ Buy | Grant | 3,553 | $0 | 6/30/2026 |
| Jorn Drappa | ▲ Buy | Option Exercise | 11,317 | $100K | 5/22/2026 |
| Jorn Drappa | ▲ Buy | Option Exercise | 15,535 | $79K | 5/22/2026 |
| James B. Tananbaum | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,176,470 | $0 | 4/1/2026 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| Foresite Labs, LLC | ▼ Sell | Other | 680,486 | $0 | 4/1/2026 |
| Foresite Capital Management VI LLC | ▼ Sell | Other | 1,176,470 | $0 | 4/1/2026 |
| Foresite Capital Management VI LLC | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| Foresite Capital Management VI LLC | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| Foresite Capital Management VI LLC | ▼ Sell | Other | 680,486 | $0 | 4/1/2026 |
| James B. Tananbaum | ▼ Sell | Other | 1,176,470 | $0 | 4/1/2026 |
| James B. Tananbaum | ▼ Sell | Other | 1,123,337 | $0 | 4/1/2026 |
| James B. Tananbaum | ▼ Sell | Other | 680,486 | $0 | 4/1/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 588,235 | $10.0M | 1/9/2026 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 117,647 | $2.0M | 1/8/2026 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 294,117 | $5.0M | 1/8/2026 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 117,647 | $2.0M | 1/8/2026 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 294,117 | $5.0M | 1/8/2026 |
| James B. Tananbaum | ▲ Buy | Open Market | 117,647 | $2.0M | 1/8/2026 |
| James B. Tananbaum | ▲ Buy | Open Market | 294,117 | $5.0M | 1/8/2026 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 64,969 | $581K | 12/5/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 70,028 | $701K | 12/5/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 51,380 | $551K | 12/5/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 66,027 | $540K | 12/4/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 100,000 | $775K | 12/3/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 96,000 | $725K | 12/2/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 86,350 | $644K | 12/1/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 38,702 | $296K | 11/28/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 48,537 | $371K | 11/26/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 72,212 | $533K | 11/21/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 72,212 | $533K | 11/21/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 72,212 | $533K | 11/21/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 125,743 | $905K | 11/20/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 190,500 | $1.2M | 11/19/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 190,500 | $1.2M | 11/19/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 190,500 | $1.2M | 11/19/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 137,772 | $904K | 11/19/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 117,374 | $727K | 11/18/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 117,374 | $727K | 11/18/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 117,374 | $727K | 11/18/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 102,652 | $621K | 11/18/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 50,000 | $280K | 11/17/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 150,000 | $839K | 11/17/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 50,000 | $280K | 11/17/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 150,000 | $839K | 11/17/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 50,000 | $280K | 11/17/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 150,000 | $839K | 11/17/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 914 | $5K | 11/17/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 276,179 | $1.4M | 11/13/2025 |
| John R. Schroer | ▲ Buy | Grant | 28,000 | $0 | 7/29/2025 |
| David M. Goldstein | ▲ Buy | Grant | 27,000 | $0 | 7/29/2025 |
| Roy C. Hardiman | ▲ Buy | Grant | 28,000 | $0 | 7/29/2025 |
| Richardson Derrick | ▲ Buy | Grant | 42,800 | $0 | 7/29/2025 |
| Sanam Pangali | ▲ Buy | Grant | 10,000 | $0 | 7/29/2025 |
| Jorn Drappa | ▲ Buy | Grant | 25,450 | $0 | 7/29/2025 |
| Mark Christopher Bradley | ▲ Buy | Grant | 26,750 | $0 | 7/29/2025 |
| Srinivas Akkaraju | ▲ Buy | Grant | 1,214,582 | — | 5/21/2025 |
| Patrick Machado | ▲ Buy | Grant | 7,064 | — | 5/21/2025 |
| AyurMaya Capital Management Company, LP | ▲ Buy | Grant | 4,493,741 | — | 5/21/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 20,000 | $87K | 5/6/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 20,000 | $87K | 5/6/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 20,000 | $87K | 5/6/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 22,002 | $116K | 5/5/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 138,368 | $634K | 5/5/2025 |
| James B. Tananbaum | ▲ Buy | Open Market | 25,000 | $116K | 5/2/2025 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 25,000 | $116K | 5/2/2025 |
| Srinivas Akkaraju | ▲ Buy | Open Market | 159,920 | $728K | 5/2/2025 |
| Foresite Capital Management VI LLC | ▲ Buy | Open Market | 25,000 | $116K | 5/2/2025 |
| Colowick Alan | ▲ Buy | Open Market | 2,300 | $17K | 4/2/2025 |
| Colowick Alan | ▲ Buy | Open Market | 16,104 | $112K | 4/1/2025 |
| Babler Martin | ▲ Buy | Open Market | 15,650 | $101K | 4/1/2025 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▲ Buy | Open Market | 2,187,500 | $35.0M | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 1,703,998 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 967,567 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,122,994 | $0 | 7/1/2024 |
| Roy C. Hardiman | ▼ Sell | Other | 175,401 | — | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,944,577 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| Mark Christopher Bradley | ▲ Buy | Grant | 20,026 | — | 7/1/2024 |
| Babler Martin | ▼ Sell | Other | 90,804 | — | 7/1/2024 |
| Babler Martin | ▲ Buy | Grant | 90,804 | — | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 622,344 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,022,398 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 312,500 | $5.0M | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 194,459 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 481,283 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 967,567 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▼ Sell | Other | 1,703,998 | $0 | 7/1/2024 |
| Foresite Labs, LLC | ▲ Buy | Open Market | 2,187,500 | $35.0M | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 1,944,577 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 1,122,994 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 622,344 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 1,022,398 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▲ Buy | Open Market | 312,500 | $5.0M | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 194,459 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 481,283 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| Foresite Capital Management V, LLC | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 1,944,577 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 1,122,994 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 622,344 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 1,022,398 | $0 | 7/1/2024 |
| James B. Tananbaum | ▲ Buy | Open Market | 312,500 | $5.0M | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 194,459 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 481,283 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 560,076 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 967,567 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 681,598 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 311,172 | $0 | 7/1/2024 |
| James B. Tananbaum | ▼ Sell | Other | 1,703,998 | $0 | 7/1/2024 |
| James B. Tananbaum | ▲ Buy | Open Market | 2,187,500 | $35.0M | 7/1/2024 |
| AyurMaya Capital Management Company, LP | ▼ Sell | Other | 8,145,966 | — | 7/1/2024 |
| AyurMaya Capital Management Company, LP | ▲ Buy | Grant | 2,500,000 | $40.0M | 7/1/2024 |
| Zhengbin Yao | ▼ Sell | Other | 23,529 | — | 7/1/2024 |
| Zhengbin Yao | ▲ Buy | Grant | 23,529 | — | 7/1/2024 |
| Srinivas Akkaraju | ▼ Sell | Other | 1,703,998 | — | 7/1/2024 |
| Srinivas Akkaraju | ▼ Sell | Other | 1,703,998 | — | 7/1/2024 |
| Srinivas Akkaraju | ▲ Buy | Grant | 1,703,998 | — | 7/1/2024 |
| Klein Sara | ▼ Sell | Other | 33,796 | — | 7/1/2024 |
| Klein Sara | ▲ Buy | Grant | 33,796 | — | 7/1/2024 |
| Roy C. Hardiman | ▲ Buy | Grant | 175,401 | — | 7/1/2024 |
| Roy C. Hardiman | ▼ Sell | Other | 6,417 | — | 7/1/2024 |
| Roy C. Hardiman | ▲ Buy | Grant | 6,417 | — | 7/1/2024 |
| David M. Goldstein | ▼ Sell | Other | 213,903 | — | 7/1/2024 |
| David M. Goldstein | ▲ Buy | Grant | 213,903 | — | 7/1/2024 |
| David M. Goldstein | ▼ Sell | Other | 2,994 | — | 7/1/2024 |
| David M. Goldstein | ▲ Buy | Grant | 2,994 | — | 7/1/2024 |
| Mark Christopher Bradley | ▼ Sell | Other | 21,978 | — | 7/1/2024 |
| Mark Christopher Bradley | ▲ Buy | Grant | 21,978 | — | 7/1/2024 |
| Mark Christopher Bradley | ▼ Sell | Other | 20,026 | — | 7/1/2024 |
| Mark Christopher Bradley | ▲ Buy | Grant | 20,026 | — | 7/1/2024 |
| Mark Christopher Bradley | ▼ Sell | Other | 20,026 | — | 7/1/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.